以ApoE和SLCO1B1基因为指导的他汀类药物在中国血脂异常患者中的临床应用

doi:10.5246/jcps.2026.03.017

摘要/Abstract

摘要：

The present study was designed to explore and validate the relationship between solute carrier organic anion transporter family member 1B1 (SLCO1B1) and apolipoprotein E (ApoE) gene polymorphisms and both the occurrence of statin-related adverse reactions and the therapeutic efficacy of lipid-lowering treatment in patients receiving statins. To address this aim, we performed a retrospective cohort study involving patients who attended a pharmacist-led outpatient clinic from January 2022 to December 2023. In total, 297 patients met the inclusion criteria and were enrolled in the analysis. Patients were stratified according to their genotypes as well as the type of statin medication administered, and the associations between genetic polymorphisms and the lipid-lowering efficacy of statins were comprehensively evaluated. The analyses revealed that serum TC and LDL-C levels showed statistically significant differences among the ε3, ε4, and overall genotype groups, both before and after adjustment (P < 0.05). Likewise, significant differences in TG levels were observed in the ε2, ε3, and overall genotype groups (P < 0.05). Importantly, post-adjustment values of TC, LDL-C, and TG were consistently and significantly lower than those recorded prior to adjustment. In addition, the incidence of statin-associated musculoskeletal symptoms was found to differ significantly among individuals with the SLCO1B1 c.388 A > G GG genotype, the SLCO1B1 c.521 T > C CT and TT genotypes, as well as in the overall study population before and after adjustment (P < 0.05). Collectively, these findings provided robust evidence that tailoring statin therapy according to ApoE and SLCO1B1 gene polymorphisms could be an effective approach for guiding clinical decision-making. Our study, therefore, offered a valuable reference for clinicians in selecting appropriate statins and in promoting individualized treatment strategies to optimize therapeutic outcomes for diverse patiens populations.

关键词: 他汀类药物, ApoE, SLCO1B1, 血脂异常

Abstract:

Key words: Statins, ApoE, SLCO1B1, Dyslipidemia

Supporting:

王鑫, 陈婉盈, 朱莹, 王华光, 安卓玲. 以ApoE和SLCO1B1基因为指导的他汀类药物在中国血脂异常患者中的临床应用[J]. 中国药学(英文版), 2026, 35(3): 255-263.

Xin Wang, Wanying Chen, Ying Zhu, Huaguang Wang, Zhuoling An. Clinical application of statins guided by ApoE and SLCO1B1 genes in Chinese patients with dyslipidemia[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(3): 255-263.

图/表 3

参考文献 26

[1]	Wilson, P.W.F.; Polonsky, T.S.; Miedema, M.D.; Khera, A.; Kosinski, A.S.; Kuvin, J.T. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019, 139. https://doi.org/10.1161/CIR.0000000000000626.
[2]	Koushki, K.; Shahbaz, S.K.; Mashayekhi, K.; Sadeghi, M.; Zayeri, Z.D.; Taba, M.Y.; Banach, M.; Al-Rasadi, K.; Johnston, T.P.; Sahebkar, A. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol. 2021, 60, 175–199.
[3]	Haynes, R.; Jiang, L.X.; Hopewell, J.C.; Li, J.; Chen, F.; Parish, S.; Landray, M.J.; Collins, R.; Armitage, J.; HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34, 1279–1291.
[4]	Hirsh, B.J.; Smilowitz, N.R.; Rosenson, R.S.; Fuster, V.; Sperling, L.S. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome. J. Am. Coll. Cardiol. 2015, 66, 184–192.
[5]	Cooper-DeHoff, R.M.; Niemi, M.; Ramsey, L.B.; Luzum, J.A.; Tarkiainen, E.K.; Straka, R.J.; Gong, L.; Tuteja, S.; Wilke, R.A.; Wadelius, M.; Larson, E.A.; Roden, D.M.; Klein, T.E.; Yee, S.W.; Krauss, R.M.; Turner, R.M.; Palaniappan, L.; Gaedigk, A.; Giacomini, K.M.; Caudle, K.E.; Voora, D. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 2022, 111, 1007–1021.
[6]	Du, Y.M.; Wang, S.Z.; Chen, Z.Y.; Sun, S.S.; Zhao, Z.G.; Li, X.G. Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: a meta-analysis. Curr. Pharm. Des. 2019, 24, 4044–4050.
[7]	Licata, A.; Giammanco, A.; Minissale, M.G.; Pagano, S.; Petta, S.; Averna, M. Liver and statins: a critical appraisal of the evidence. Curr. Med. Chem. 2019, 25, 5835–5846.
[8]	Sivkov, A.; Chernus, N.; Gorenkov, R.; Sivkov, S.; Sivkova, S.; Savina, T. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia. Lipids. Health Dis. 2021, 20, 157.
[9]	Osanlou, O.; Pirmohamed, M.; Daly, A.K. Pharmacogenetics of adverse drug reactions. Pharmacogenetics. Amsterdam: Elsevier. 2018, 155–190.
[10]	Wilke, R.A.; Ramsey, L.B.; Johnson, S.G.; Maxwell, W.D.; McLeod, H.L.; Voora, D.; Krauss, R.M.; Roden, D.M.; Feng, Q.; Cooper-DeHoff, R.M.; Gong, L.; Klein, T.E.; Wadelius, M.; Niemi, M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 2012, 92, 112–117.
[11]	Zhao, X.N.; Sun, Q.; Cao, Y.Q.; Ran, X.; Cao, Y. Association between apolipoprotein gene polymorphisms and hyperlipidemia: a meta-analysis. BMC Genom. Data. 2021, 22, 14.
[12]	Wilke, R.A.; Lin, D.W.; Roden, D.M.; Watkins, P.B.; Flockhart, D.; Zineh, I.; Giacomini, K.M.; Krauss, R.M. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 2007, 6, 904–916.
[13]	Yousuf, F.A.; Iqbal, M.P. Apolipoprotein E (Apo E) gene polymorphism and coronary heart disease in Asian populations. Pak. J. Pharm. Sci. 2015, 28, 1439–1444.
[14]	Shatwan, I.M.; Winther, K.H.; Ellahi, B.; Elwood, P.; Ben-Shlomo, Y.; Givens, I.; Rayman, M.P.; Lovegrove, J.A.; Vimaleswaran, K.S. Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors. Lipids. Health Dis. 2018, 17, 98.
[15]	Bennet, A.M.; Di Angelantonio, E.; Ye, Z.; Wensley, F.; Dahlin, A.; Ahlbom, A.; Keavney, B.; Collins, R.; Wiman, B.; de Faire, U.; Danesh, J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007, 298, 1300.
[16]	Zhou, T.B.; Li, H.Y.; Zhong, H.Z.; Zhong, Z.Q.; Lin, S.J. Association of apoE gene polymorphisms with lipid metabolism in renal diseases. Afr. H. Sci. 2020, 20, 1368–1381.
[17]	Minihane, A.M.; Jofre-Monseny, L.; Olano-Martin, E.; Rimbach, G. ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation: Symposium on ‘Molecular basis for diseases’. Proc. Nutr. Soc. 2007, 66, 183–197.
[18]	Nabatchian, F.; Khaghani, S.; Miri, R.; Farzaneh, Z.; Tabei, S.M.B. Apolipoprotein E polymorphism, paraoxonase-1 activity and coronary artery disease: is there a link? Pak. J. Med. Sci. Q. 2008, 24, 204–208.
[19]	Niemi, M.; Pasanen, M.K.; Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 2011, 63, 157–181.
[20]	Turner, R.M.; Pirmohamed, M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J. Clin. Med. 2020, 9, 22.
[21]	Zintzaras, E.; Kitsios, G.D.; Triposkiadis, F.; Lau, J.; Raman, G. APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J. 2009, 9, 248–257.
[22]	Lagos, J.; Zambrano, T.; Rosales, A.; Salazar, L. APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects. Int. J. Mol. Sci. 2015, 16, 7890–7899.
[23]	Hu, M.; Mak, V.W.L.; Tomlinson, B. Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. J. Clin. Lipidol. 2012, 6, 585–592.
[24]	Voora, D.; Shah, S.H.; Spasojevic, I.; Ali, S.; Reed, C.R.; Salisbury, B.A.; Ginsburg, G.S. The SLCO1B15 Genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol.* 2009, 54, 1609–1616.
[25]	Voora, D.; Baye, J.; McDermaid, A.; Narayana Gowda, S.; Wilke, R.A.; Nicole Myrmoe, A.; Hajek, C.; Larson, E.A. SLCO1B15 allele is associated with atorvastatin discontinuation and adverse muscle symptoms in the context of routine care. Clin. Pharmacol. Ther.* 2022, 111, 1075–1083.
[26]	Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russ. J. Cardiol. 2020, 25, 3826.